Antidepressants and pregnancy: Risks and benefits for the mother and child;Antidépresseurs et grossesse - Risques et bénéfices pour la mère et l'enfant

Medecine/Sciences

Volumn 23, Issue 11, 2007, Pages 957-960

  Bérard, Anick ^a   Ramos, Élodie ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT;

CONCEPTION; DEPRESSION; FETUS RISK; GESTATION PERIOD; HUMAN; PREGNANCY; RELAPSE; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; WITHDRAWAL SYNDROME;

EID: 36549085578     PISSN: 07670974     EISSN: None     Source Type: Journal    
DOI: 10.1051/medsci/20072311957     Document Type: Review

References (28)

1. Wisner KL, Gelenberg AJ, Leonard H, et al. Pharmacologic treatment of depression during pregnancy. JAMA 1999 ; 282 ; 1264-9.
2. Gentile S. The safety of newer antidepressants in pregnancy and breastfeeding. Drug Saf 2005 ; 28 : 137-52.
3. Koren G, Pastuszak A, Ito S. Drugs in pregnancy. N Engl J Med 1998 ; 338 : 1128-37.
4. Bérard A, Oraichi D. Development of a surveillance and signal detection system to monitor medication exposure during pregnancy and lactation. Pharmacoepidemiol Drug Saf 2004 ; 13 : S1-334 (253).
5. US Department of Health and Human Services. Mental health : a report of the surgeon general. Executive summary of 1999. http://www.surgeongeneral.gov/ library/mentalhealth/pdfs/c4.pdf.
6. International Clearinghouse for Birth Defects Monitoring Systems, Annual report Rome: ICBDMS, 2003.
7. Einarson A, Selby P, Koren G. Abrupt discontinuation of psychotropic drugs during pregnancy : fear of teratogenic risk and impact of counselling. J Psychiatry Neurosci 2001 ; 26 : 44-8.
8. Ramos E, Oraichi D, Rey E, et al. Prevalence and predictors of antidepressant use in a cohort of pregnant women. Br J Obstet Gynecol 2007 ; 114 : 1055-64.
9. Health Canada. Health Canada endorsed important safety information on Paxil (paroxetine), 2005. http://www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/ prof/2005/paxil_3_hpc-cps_f.html
10. US Food and Drug Administration. FDA Public Health Advisory Paroxetine of 2005. http://www.fda.gov/cder/drug/advisory/paroxetine200512.htm
11. Chambers CD, Hernandez-Diaz S, Van Marter LJ, et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med 2006 ; 354 : 579-87.
12. Bérard A, Ramos E, Rey E, et al. First trimester exposure to paroxetine and risk of cardiac malformations in infants : the importance of dosage. Birth Defects Res B Dev Reprod Toxicol 2007 ; 80 : 18-27.
13. Oberlander TF, Warburton W, Misri S, et al. Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Arch Gen Psychiatry 2006 ; 63 : 898-906.
14. Cohen LS, Altshuler LL, Harlow BL, et al. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA 2006 ; 295 : 499-507.
15. Lou HC, Hansen D, Nordentoft M, et al. Prenatal stressors of human life affect fetal brain development. Dev Med Child Neurol 1994 ; 36 : 826-32.
16. Orr ST, Miller CA. Maternal depressive symptoms and the risk of poor pregnancy outcome. Review of the literature and preliminary findings. Epidemiol Rev 1995 ; 17 : 165-71.
17. Dominguez RA, Goodnick PJ. Adverse events after the abrupt discontinuation of paroxetine. Pharmacotherapy 1995 ; 15 : 778-80.
18. Buist A. Perinatal depression : assessment and management. Aust Fam Physician 2006 ; 35 : 670-3.
19. Beck CT. The effects of postpartum depression on maternal-infant interaction : a meta-analysis. Nurs Res 1995 ; 44 : 298-304.
20. Yoshida K, Smith B, Craggs M, Kumar RC. Investigation of pharmacokinetics and of possible adverse effects in infants exposed to tricyclic antidepressants in breast-milk. J Affect Disord 1997 ; 43 : 225-37.
21. Wisner KL, Perel JM. Serum nortriptyline levels in nursing mothers and their infants. Am J Psychiatry 1991 ; 148 : 1234-6.
22. Wisner KL, Perel JM, Foglia JP. Serum clomipramine and metabolite levels in four nursing mother-infant pairs. J Clin Psychiatry 1995 ; 56 : 17-20.
23. Wisner KL, Perel JM, Findling RL. Antidepressant treatment during breast-feeding. Am J Psychiatry 1996 ; 153 : 1132-7.
24. Baum AL, Misri S. Selective serotonin-reuptake inhibitors in pregnancy and lactation. Harv Rev Psychiatry 1996 ; 4 : 117-25.
25. Ramos E, St-André M, Rey E, Bérard A. Risk of congenital malformations associated with duration of exposure to antidepressants during the gestational period. Br J Psychiatry 2007 (accepté pour publication).
26. Blier P. Pregnancy, depression, antidepressants and breast-feeding. J Psychiatry Neurosci 2006 ; 31 : 226-8.
27. Oberlander TF, Reebye P, Misri S, et al. Externalizing and attentional behaviors in children of depressed mothers treated with a selective serotonin reuptake inhibitor antidepressant during pregnancy. Arch Pediatr Adolesc Med 2007 ; 161 : 22-9.
28. Rubinow DR. Antidepressant treatment during pregnancy : between Scylla and Charybdis. Am J Psychiatry 2006 ; 163 : 954-6.